Introduction
============

Human immunodeficiency virus (HIV) infection is propagated primarily via blood transfusion (before 1985), intravenous drug use, professional exposure in medical institutes, sexual transmission and mother-to-child transmission ([@b1-etm-0-0-4067],[@b2-etm-0-0-4067]).

Historically, hepatitis C virus (HCV) infection has developed in three waves: i) Medical care through needles and syringes reused without sterilization; ii) blood transfusion before 1991; iii) and through intravenous drug injection or the sharing of straws for cocaine inhalation ([@b3-etm-0-0-4067]).

HCV infection is often observed among HIV-infected persons, with one-third of HIV-infected Americans and 7 million worldwide being coinfected ([@b4-etm-0-0-4067],[@b5-etm-0-0-4067]). HIV coinfection deteriorates HCV disease, increasing the likelihood of cirrhosis and HCV-related mortality ([@b6-etm-0-0-4067],[@b7-etm-0-0-4067]).

There are 33.3 million people globally living with HIV infection ([@b8-etm-0-0-4067]). It is estimated that 20--30% of HIV patients are also infected with hepatitis C (HCV) ([@b9-etm-0-0-4067]). In China, small sample studies suggest that 8.25--56.9% of HIV-infected persons were simultaneously infected with HCV ([@b10-etm-0-0-4067]--[@b14-etm-0-0-4067]). Delayed testing for HIV and HCV is common among patients at methadone clinics in Guangdong, with numerous patients experiencing delays of ≥2 months ([@b13-etm-0-0-4067],[@b14-etm-0-0-4067]). Early diagnosis and enrollment in care is particularly crucial in a highly populated country such as China; thus, expediting HIV and HCV testing is important ([@b15-etm-0-0-4067]).

Guangxi province is a high endemic area of HIV infection in China \[the cumulated report number of HIV-infected persons is ranked second in the country ([@b16-etm-0-0-4067])\], which also has a high incidence of viral liver disease and hepatocellular carcinoma ([@b17-etm-0-0-4067]). Based on frequent HIV/HCV coinfection in other areas, there is a crucial requirement to investigate the HCV infection status in HIV-infected people. Furthermore, there are likely to be numerous HCV-infected persons among the HIV-infected population for which the diagnosis of HCV has been missed due to the diagnosis being made only on the basis of HCV antibody detection.

Materials and methods
=====================

### Ethics statement

This study was approved by the Health Bureau of Guangxi Province and the Ethics Review Committee at Guangxi Medical University (Nanning, China). Written informed ethical consent was provided by clinical directors who answered the questionnaire. All patients gave their written consent for their information to be used for research.

### Study population

This study was performed between August 2008 and January 2011. The participants were recruited through acquired immune deficiency syndrome (AIDS) voluntary counselling and testing clinics, prisons, addiction treatment centers, hospitals and communities from Liuzhou and Qinzhou cities in Guangxi province. A total of 300 individuals with HIV-1 infection were recruited. All participants or their guardians voluntarily signed a consent form. Written informed ethical consent was provided by professionals who answered the questionnaire. A total of 41 patients who were only infected with hepatitis C were recruited from the First Affiliated Hospital of Guangxi Medical University to serve as the control group.

All participants were analyzed to characterize their serological status toward both HIV \[screening and confirmation tests ([@b18-etm-0-0-4067])\] and HCV \[screening, serological confirmation, search for HCV-RNA by polymerase chain reaction (PCR) and genotyping\] as described below. Samples of serum and plasma (10 ml) were prepared from venous whole blood.

### Reagents

Hepatitis C virus antibody diagnostic kits were purchased from Shanghai Kehua Bio-Engineering Co., Ltd., (Shanghai, China). QIAamp Viral RNA Mini kit was obtained from Qiagen (Hilden, Germany). A Revert Aid First Strand cDNA Synthesis kit was purchased from Fermentas, Inc., (Burlington, ON, Canada). Restriction endonucleases *Bsr*BI, *Hae*II, *Hinf*I, *Bst*UI, *Hae*Ш and *Apo*l were obtained from New England Biolabs (Ipswich, MA, USA).

### Enzyme-linked immunosorbent assay (ELISA)

Flavicheck-HCV, a commercial third generation, rapid, qualitative, two-site sandwich immunoassay test device was employed according to the manufacturer\'s instructions (Tulip Diagnostics (P), Ltd., Goa, India). The kit was used to detect total antibodies specific to HCV in serum or plasma by using a multiepitope recombinant peptide antigen that is broadly cross-reactive to all major HCV genotypes.

### Nested-PCR and reverse transcription-quantitative PCR (RT-qPCR)

Total RNA was isolated from 140 µl plasma using a QIAamp Viral RNA Mini kit according to the manufacturer\'s instructions (Qiagen). RNA samples were DNase treated using an RQ1 RNase-Free DNase kit (Promega, Madison, WI, USA), according to the manufacturer\'s instructions. Nucleic acids were then aliquoted, and one aliquot was reverse-transcribed according to the SuperScript III First-Strand cDNA Synthesis SuperMix kit protocol using random hexamers (Invitrogen; ThermoFisher Scientific, Inc., Carlsbad, CA, USA). cDNA was synthesized from total RNA using reverse transcriptase using a First Strand cDNA synthesis kit (Fermentas, Inc.). The cDNA was amplified by nested PCR using a Tiangen 2X PCR mix kit (Tiangen Biotech Co., Ltd., Bejing, China) or by RT-qPCR using SYBR Green SuperMix (Bio-Rad Laboratories, Inc., Hercules, CA, USA) according to the manufacturers\' instructions. The PCR cycling was conducted as follows: In the first round, the amplification mixture comprised 5.0 µl cDNA, 12.5 µl pre-mixed solution of Tiangen 2X PCR mix and 0.5 µl of each primer (P1 and P2). The enzyme was diluted with 6.5 µl water, and the total reaction volume was 25.0 µl. The reaction conditions were as follows: 94°C for 5 min; 94°C for 45 sec, 62°C for 30 sec, and 72°C for 20 sec for 35 cycles; followed by 72°C for 5 min. In the second round, the amplification mixture comprised 3.0 µl product from the first round, 12.5 µl pre-mixed solution of Tiangen 2X PCR mix, 0.4 µl each primer (P3 and P4). The enzyme was diluted with 8.7 µl water, and the total reaction volume was 25.0 µl. The extension time in the second round was 15 sec, and all other times were as in the first round. For the RT-qPCR analysis, all experiments were performed in triplicate. The sample input was normalized against its own critical threshold (Cq) value of the housekeeping gene GAPDH. Primer sequences and PCR conditions used in this study are listed in [Table I](#tI-etm-0-0-4067){ref-type="table"}. The 2^−ΔΔCq^ method ([@b19-etm-0-0-4067]) was used to calculate the expression levels.

### PCR product sequencing

The nested PCR products and sense primer were used for sequencing reaction. PCR products were recovered according to the manufacturer\'s instructions (Fermentas, Inc.). The sequencing was performed using the Sanger dideoxy method ([@b20-etm-0-0-4067]). This was followed by detection of the HCV sequence using GeneBank (<https://www.ncbi.nlm.nih.gov/genbank/>), BBLAST (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>), Clustalx (<http://www.clustal.org/clustal2/>) and BioEdit software (<http://www.mbio.ncsu.edu/BioEdit/page2.html>).

### HCV genotype test

Restriction fragment length polymorphism (RFLP) analysis was conducted using the method described by Chinchai *et al* ([@b21-etm-0-0-4067],[@b22-etm-0-0-4067]). In RFLP, the nested PCR products of RNA positive samples (20--30 µl) were digested using the restriction enzymes *Acc*1, *Mbo*l and *Bst*N1 and incubated at 37°C for overnight in a specific endonuclease buffer (Shanghai Biological Engineering Co., Ltd., Shanghai, China). The digested product was loaded onto 3% nusieve agarose gel and the restriction pattern was analyzed using a Gel-Doc 2000 System (Bio-Rad Laboratories, Inc.).

### Data analysis

Data were analyzed using SPSS software version 17.0 (SPSS, Inc., Chicago, IL, USA). Chi-square (χ^2^) test was utilized to compare variables. P\<0.05 was considered to indicate a statistically significant difference. Odds ratio (OR) and 95% confidence interval (CI) were used to measure the strength of association.

Results
=======

### Demographics and epidemiological characteristics

Demographic data were collected regarding the participant\'s gender, age, ethnicity, education, employment and marital status ([Table II](#tII-etm-0-0-4067){ref-type="table"}). Among the 300 HIV positive participants, 195 were male and 105 were female; the oldest patient was 88 years old and the youngest was 2 years old; the mean age was 37.39±13.73 years. Among all participants, 201 were of Han ethnicity and 99 were of minority ethnicity. Among the viral hepatitis C and HIV-infected participants, 103 were Han, while 43 patients were of the Zhuang ethnicity. The majority of the participants had no fixed occupation (54.7%); the majority of the participants were unmarried or single (53.33%); among the HIV positive patients in Liuzhou and Qinzhou, there were no significant differences in HCV infection rate ([Table II](#tII-etm-0-0-4067){ref-type="table"}).

### Predominant route of transmission in HIV and HCV coinfected participants

The prevalence of HCV infection was 48.67% (146/300) among the HIV infected study population. Among the 101 individuals who were drug users, 93 (92.08%) exhibited HIV/HCV coinfection. One of the six subjects that had received a blood transfusion was infected with HCV (16.67%). One of the five subjects suffered HIV from vertical transmission was infected with HCV (20%). Among the 188 subjects that suffered from a history of sexually transmitted diseases, 51 persons were infected with HCV (27.13%). With respect to sexual behavior, \~69.18% of the subjects had more than one sexual partner. The rate of coinfection differed between transmission route according to the results of the χ^2^ test ([Table III](#tIII-etm-0-0-4067){ref-type="table"}).

### Gene sequencing of HCV positive serum samples

Five cases of HCV RNA-positive serum samples were randomly selected, and nested PCR products were sequenced. The results showed that the sequences of the samples were the same as HCV 5′ untranslated region in GeneBank by blasting HCV database ([Fig. 1](#f1-etm-0-0-4067){ref-type="fig"}).

### HCV prevalence at the RNA level

HCV RNA quantification was conducted using nested PCR. The results showed that among the 146 HCV antibody-positive serum samples, there were 114 HCV RNA positive samples. However, there were 41 HCV RNA positive samples among the HCV antibody-negative serum samples ([Fig. 2](#f2-etm-0-0-4067){ref-type="fig"}).

### HCV genotypes in the Guangxi province population

The digested results showed that among the 41 study participants positive for HCV RNA but negative for HCV antibody, the prevalence rates of the 1b, 1a, 3a and 4a genotypes were 22 (53.7%), 3 (7.3%), 6 (14.6%) and 5 (12.2%), respectively. Among the 146 study participants that were positive for HCV antibody, the prevalence of the 1b, mixed, 6a, 3b, 1a, 3a, 2a and 2b genotypes were 31 (27.2%), 27 (23.7%), 18 (15.8%), 14 (12.3%), 10 (8.8%), 5 (4.4%), 5 (4.4%) and 4 (3.5%), respectively ([Table IV](#tIV-etm-0-0-4067){ref-type="table"}).

### Differences between positive HCV antibody and HCV RNA test results

Among the 300 study participants tested for anti-HCV antibodies and HCV RNA, 114 were positive for both, accounting for 38%. A total of 41 participants were anti-HCV negative and HCV RNA positive, accounting for 13.7%. A total of 32 participants were anti-HCV positive and HCV RNA negative, accounting for 10.67% (32/300) of all patients. Among the 300 individuals analyzed, 113 were negative for anti-HCV and HCV RNA, accounting for 37.67%. Among the anti-HCV negative participants, 41 were HCV RNA positive, accounting for 13.7% (41/300) of all patients ([Table V](#tV-etm-0-0-4067){ref-type="table"}).

### Characteristics of the HCV antibody negative but HCV RNA positive participants

Among the 41 study participants positive for HCV RNA but negative for HCV antibody, there were 23 male and 18 female subjects, with an average age of 39.51±16.32 years, and the viral load differed, although not significantly, among age groups ([Table VI](#tVI-etm-0-0-4067){ref-type="table"}). The prevalence of HCV RNA differed according to transmission route; most patients contracted HCV sexually and the second most prevalent route was drug-related transmission ([Fig. 3](#f3-etm-0-0-4067){ref-type="fig"}); however, no significant differences in HCV RNA load were observed between the different transmission routes ([Table VII](#tVII-etm-0-0-4067){ref-type="table"}).

Discussion
==========

This study was aimed at determining the HCV infection prevalence and HCV genotype in HIV infected patients as well as obtaining demographic and epidemiological characteristics of HIV/HCV coinfection patients in the Guangxi province of China.

With respect to demographic characteristics, the majority of the HIV/HCV coinfection participants were males, and aged 20--40 years. The majority of the HIV/HCV coinfection participants had no fixed occupation, were unmarried or single, and 61.6% were drug users. The results showed that sexually active, young, single individuals with no fixed occupation were at the highest risk of HIV/HCV coinfection.

Hepatitis C virus (HCV) is an RNA virus which has been known to cause acute and chronic necroinflammatory disease of the liver ([@b23-etm-0-0-4067],[@b24-etm-0-0-4067]). HCV is the leading cause of end-stage liver disease and hepatocellular carcinoma ([@b25-etm-0-0-4067]). HIV is known to have a negative impact on the natural disease outcome and immune response of HCV infection, whereas the reverse remains unclear ([@b26-etm-0-0-4067]). HIV infection is propagated primarily via blood transfusion (before 1985), intravenous drug use, professional exposure in medical personnel, sexual transmission and mother-to-child transmission ([@b1-etm-0-0-4067],[@b2-etm-0-0-4067]). Furthermore, HCV contamination is caused by intravenous drug use and blood transfusion (before 1991), long term hemodialysis, organ transplantation and receipt of tattoos from unsanitary facilities ([@b27-etm-0-0-4067]). According to above statements, HIV and HCV share numerous transmission routes, and thus coinfection with HCV and HIV is quite common. In the present study, drug addiction, particularly intravenous drug use, was the primary transmission route in HIV/HCV coinfection subjects, which indicated that it is necessary to screen for HCV in HIV positive intravenous drug users. A number of studies have suggested that the presence of HIV infection accelerates the course of HCV-related liver disease in HCV/HIV coinfected patients ([@b26-etm-0-0-4067],[@b28-etm-0-0-4067],[@b29-etm-0-0-4067]). The frequency of HCV transmission to sexual partners is significantly higher when HIV virus is also transmitted ([@b30-etm-0-0-4067]). HIV is known to impair the T-helper type 1 immune response, which in turn changes the response of immune cells to HCV ([@b31-etm-0-0-4067]). This facilitates increased HCV replication and consequently easier infection. Epidemiologic studies have identified HIV as an independent factor in HCV transmission and acquisition since the earliest days of the HIV epidemic ([@b32-etm-0-0-4067]). HIV-infected persons are less likely to spontaneously clear HCV, and their HCV RNA set point tends to be higher, making them more infectious to their partners compared with HCV-monoinfected individuals ([@b33-etm-0-0-4067]). A previous study showed that coinfected men were more likely than HIV-uninfected men to produce HCV RNA in their semen ([@b34-etm-0-0-4067]). HIV-infected individuals may have compromised gastrointestinal mucosal barriers and be more likely to have chronic inflammation, facilitating HCV transmission ([@b35-etm-0-0-4067]). The present results indicate that intravenous drug use, sexual transmission and blood transfusion are the primary transmission routes of HIV/HCV coinfection in patients from Guangxi.

ELISA is the conventional method used to detect HCV antibody; however, the shortcoming of ELISA is the long window-period prior to antibodies becoming detectable and screening hepatitis C only by ELISA in HIV-infected persons is likely to miss the identification of some cases. Therefore, HCV antibody can not be used as an early diagnostic marker of HCV infection. However, serum HCV RNA detection could be a reliable indicator due to its shorter window-period and higher sensitivity. It has been reported that \~11% of HIV/HCV coinfection patients are HCV antibody negative ([@b36-etm-0-0-4067]). Liu *et al* showed that in HIV/HCV coinfection patients in Beijing, the nucleic acid positive rate was 19.5% in HCV antibody-negative group ([@b37-etm-0-0-4067]). In the present study, it was found that in HIV/HCV coinfection persons in Guangxi, the nucleic acid positive rate was 26.62% in HCV antibody-negative group, which was higher than reported previously.

Although the coinfection of HIV with HCV has been recognized worldwide, few studies have been conducted to investigate HIV/HCV coinfection prevalence in Guangxi and the association between prevalence and transmission route, particularly in patients infected via sexual transmission. The present study was conducted on different populations coinfected with HIV/HCV, providing important reference data for prevention and treatment. The data show that HIV/HCV coinfection prevalence was \~48.67%, which is higher reports from outside of China ([@b30-etm-0-0-4067],[@b38-etm-0-0-4067]--[@b41-etm-0-0-4067]), and higher than the prevalence of HCV among domestic general populations ([@b42-etm-0-0-4067]), which indicates that HIV/HCV coinfection is a serious health concern. In addition, the results indicate that besides HCV, AIDS infected persons are also liable to coinfect with other hepatitis virus, tuberculosis and syphilis, which all indicate that it is important to improve approaches for the management of HIV coinfection.

In conclusion, the present data indicate that HIV/HCV coinfection is a serious health concern in the Guangxi province of China. Therefore, it may be necessary to manage and control HIV/HCV progression to prevent their potential outbreak or spread among the general population, on the basis of infection status, transmission routes and risk behaviors.

This study was financially supported by the fourth round of the Global Fund/Sino-British AIDS Project (grant no. 2008OR52).
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###### 

HCV primer sequences, annealing temperatures and product sizes for the nested PCR analyses.

  Primer                Primer sequence                        Annealing temperature (°C)   Product size (bp)
  --------------------- -------------------------------------- ---------------------------- -------------------
  Nested outer primer   Forward: 5′-TGAGGAACTACTGTCTTCACG-3′   62                           258
                        Reverse: 5′-AGCACCCTATCAGGCAGTACC-3′                                
  Nested inner primer   Forward: 5′-GGGAGAGCCATAGTGGTCTG-3′    62                           186
                        Reverse: 5′-CACTCGCAAGCACCCTATC-3′                                  

HCV, hepatitis C virus; PCR, polymerase chain reaction.

###### 

Sociodemographic characteristics of HIV/HCV coinfected persons.

                                              HCV                     
  --------------------------- ----- --------- ----- --------- ------- --------
  Gender                                                      13.37   \<0.01
    Male                      195   65.0      110     59.46           
    Female                    105   35.0      36      34.29           
  Age (years)                                                 13.69   0.02
    \<20                      6       2.0     2       33.33           
    20--29                    89    29.7      42      47.19           
    30--39                    105   35.0      63    60.0              
    40--49                    50    16.7      25    50                
    50--59                    22      7.3     6       27.27           
    ≥60                       28      9.3     8       28.57           
  Ethnicity                                                   1.62    0.20
    Han                       201   67.0      103     51.24           
    Minority                  99    33.0      43      43.43           
  Occupation                                                  21.94   \<0.01
    Unemployed                164   54.7      100     60.98           
    Employed                  136   45.3      46      33.82           
  Education                                                   9.00    0.03
    ≤Primary school           51      17.0    30      58.82           
    Junior high school        201     67.0    94      46.77           
    High school/polytechnic   30      10.0    18    60.0              
    ≥College                  18      6.0     4       22.22           
  Marital status                                              18.85   \<0.01
    Married                   95      31.67   33      34.74           
    Unmarried                 165     53.33   99    60.0              
    Divorced/widowed          40      15.0    14    35.0              
  Region                                                      0.21    0.91
    Liuzhou                   141   47.0      68      48.23           
    Qinzhou                   159   53.0      78      49.06           

HIV, human immunodeficiency virus; HCV, hepatitis C virus.

###### 

Distribution of HIV/HCV coinfected patients in different transmission routes.

  Transmission route      Participants (n)   HIV/HCV coinfection   Coinfection rate (%)   χ^2^    P-value
  ----------------------- ------------------ --------------------- ---------------------- ------- ---------
  Drug-related            101                  93                  92.08                          
  Sex-related             188                  51                  27.13                          
  Vertical transmission       5                  1                 20.0                   127.4   \<0.001
  Blood transfusion           6                  1                 16.67                          
  Total                   300                146                   48.67                          

HIV, human immunodeficiency virus; HCV, hepatitis C virus.

###### 

Comparison of HCV genotype distribution between two groups (n=155).

             Genotype                                            
  ---------- ---------- ---- --- --- ----- ----- --- ----- ----- ------
  Negative     3        22   0   2     6     1   5     2     0     41
  Positive   10         31   5   4     5   14    0   18    27    114
  Total      13         53   5   6   11    15    5   20    27    155

The overall HCV RNA positive participants were 155, HCV genotypes were diverse among the 155 human immunodeficiency virus/HCV coinfection subjects, and the main type were 1b, mixed subtype, 6a, 3b and 3a. HCV, hepatitis C virus.

###### 

Comparison of positive HCV antibody and HCV RNA (n=300).

             HCV RNA          
  ---------- --------- ------ -----
  Positive   114         32   146
  Negative     41      113    154
  Total      155       145    300

HCV, hepatitis C virus.

###### 

Comparison of HCV RNA load between three age groups (n=41).

  Age (years)   Cases   HCV RNA load (log)   F      P-value
  ------------- ------- -------------------- ------ ---------
  \<30          15      5.84±1.29                   
  30--45        12      6.40±0.76            0.83   0.44
  \>45          14      5.84±1.52                   

HCV, hepatitis C virus.

###### 

Comparison of HCV RNA load in different transmission routes (n=41).

  Transmission   Cases   HCV RNA load (log)   t      P-value
  -------------- ------- -------------------- ------ ---------
  Sex            33      5.94±1.24            0.31   0.74
  Drugs            8     6.39±0.94                   

HCV, hepatitis C virus.

[^1]: Contributed equally
